IL17A and ovarian carcinoma: Increasing studies have illustrated that Th17/IL-17a axis may promote the progression of solid tumors (lung, liver and ovarian cancers) and hematologic cancers (chronic lymphocytic leukemia and myeloma) [31, 53–56].